EFFICACY AND SAFETY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (SPIRIT 2)
article
OA: closed
CC0
⤵ 7 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This Phase 3 trial evaluated the efficacy and safety of relugolix combination therapy for treating endometriosis-associated pain.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (7)
- Endometriosis: Molecular Pathophysiology and Recent Treatment Strategies-Comprehensive Literature Review 2024
- Novel pharmacological therapies for the treatment of endometriosis 2022
- Advances in targeting estrogen synthesis and receptors in patients with endometriosis 2022
- The latest advances in the pharmacological management of endometriosis 2022
- Medical treatments of endometriosis: a review 2022
- Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review 2021
- Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapies 2021
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-06-05T02:00:03.366016+00:00
License: CC0
· commercial use OK